Krystal Biotech (NASDAQ:KRYS) EVP Sells 1,000 Shares of Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) EVP John Charles Thomas sold 1,000 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares in the company, valued at approximately $347,270. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Charles Thomas also recently made the following trade(s):

• On Tuesday, May 26th, John Charles Thomas sold 642 shares of Krystal Biotech stock. The shares were sold at an average price of $302.03, for a total transaction of $193,903.26.

Krystal Biotech Price Performance

Krystal Biotech stock traded up $12.32 during midday trading on Friday, reaching $372.25. 1,307,695 shares of the company traded hands, compared to its average volume of 308,876. Krystal Biotech, Inc. has a 12 month low of $130.50 and a 12 month high of $376.28. The business has a 50 day moving average of $302.65 and a two-hundred day moving average of $276.02. The firm has a market capitalization of $10.97 billion, a price-to-earnings ratio of 49.77 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. The business had revenue of $116.36 million during the quarter, compared to analyst estimates of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. As a group, equities analysts forecast that Krystal Biotech, Inc. will post 7.66 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings raised shares of Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday, June 16th. Evercore restated an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. TD Cowen upped their target price on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Finally, Wolfe Research assumed coverage on shares of Krystal Biotech in a research report on Friday, March 27th. They issued a “peer perform” rating on the stock. Ten analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $340.56.

Institutional Trading of Krystal Biotech

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. UMB Bank n.a. grew its holdings in Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after buying an additional 37 shares in the last quarter. Optimize Financial Inc boosted its position in shares of Krystal Biotech by 1.4% during the fourth quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock worth $704,000 after acquiring an additional 40 shares during the last quarter. Perigon Wealth Management LLC boosted its position in shares of Krystal Biotech by 0.5% during the fourth quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock worth $2,211,000 after acquiring an additional 41 shares during the last quarter. Regal Investment Advisors LLC grew its stake in Krystal Biotech by 1.0% during the fourth quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock valued at $1,075,000 after acquiring an additional 44 shares in the last quarter. Finally, Torray Investment Partners LLC grew its stake in Krystal Biotech by 0.4% during the first quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock valued at $3,108,000 after acquiring an additional 47 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.